Benjamin Garmezy, MD

No bio available.

Financial relationships

  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Janssen
    Topic:
    Research Funding and Consulting - Institution
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Janux Therapeutics
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Jubilant Therapeutics
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Kineta
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Kinnate Biopharma
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Loxo
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Mink Therapeutics
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Nuvation Bio
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Profound Bio
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    TEON Therapeutics
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023

Pages

Return to PARP Inhibitors in Prostate Cancer – Recent Updates and Implications for Clinical Practice